Stock CLDI CALIDI BIOTHERAPEUTICS, INC.
Add to a list
To use this feature you must be a member
Log inSign up

News Calidi Biotherapeutics, Inc.

Equities

CLDI

US3207031010

Real-time Estimate Cboe BZX
Other stock markets
 16:53:13 29/04/2024 BST 		5-day change 1st Jan Change
0.22 USD +36.90% Intraday chart for Calidi Biotherapeutics, Inc. +16.92% -87.92%
04-16 Calidi Biotherapeutics Prices $6.1 Million Offering MT
03-21 H.C. Wainwright Lowers Price Target on Calidi Biotherapeutics to $2 From $11, Maintains Buy Rating MT

Summary

Search
See the results
Unlock all the news on all businesses: Never miss an investment opportunity again!
100% Free Registration
Join Calidi Biotherapeutics Exclusive Live Investor Webinar and Q&A Session on April 24
AQ
Join Calidi Biotherapeutics’ Exclusive Live Investor Webinar and Q&A Session on April 24
BU
Calidi Biotherapeutics, Inc. Announces Closing of $6.1 Million Public Offering
BU
Calidi Biotherapeutics Prices $6.1 Million Offering
MT
Calidi Biotherapeutics, Inc. Announces Pricing of $6.1 Million Public Offering
BU
Calidi Biotherapeutics Presents New Data on the Mechanisms of Action for Virotherapy-Loaded Stem Cells Used in the Company's Novel Immunotherapies at the AACR Annual Meeting 2024
AQ
Calidi Biotherapeutics Presents New Data on the Mechanisms of Action for Virotherapy-Loaded Stem Cells Used in the Company’s Novel Immunotherapies at the AACR Annual Meeting 2024
BU
H.C. Wainwright Lowers Price Target on Calidi Biotherapeutics to $2 From $11, Maintains Buy Rating
MT
Calidi Biotherapeutics, Inc. announced that it has received $3.5 million in funding
CI
Calidi Biotherapeutics Reports Fourth Quarter and Full-Year 2023 Operating and Financial Results
BU
Calidi Biotherapeutics and City of Hope Announce Funding from the California Institute for Regenerative Medicine (CIRM) to Advance CLD-101 (NeuroNova) in Ovarian Cancer
BU
Calidi Biotherapeutics, Inc. announced that it expects to receive $3.5 million in funding
CI
Calidi Biotherapeutics to Highlight Novel Systemic Enveloped Oncolytic Virotherapy Platform Designed to Target All Tumor Sites at Upcoming Conference
BU
Sector Update: Health Care Stocks Firmer Late Afternoon
MT
Calidi Biotherapeutics to Sell Common Stock
MT
Calidi Biotherapeutics, Inc. announced that it has received $1 million in funding
CI
Calidi Biotherapeutics Announces the Appointment of Three New Members to its Scientific and Medical Advisory Board
BU
Calidi Biotherapeutics, Inc. Announces Scientific and Medical Advisory Board Appointments
CI
Calidi Biotherapeutics, Inc.(NYSEAM:CLDI) added to S&P TMI Index
CI
Calidi Biotherapeutics Announces Appointment of Pharmaceutical Industry Veteran David LaPre to its Board of Directors
AQ
No results for this search
All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Filters

Search

Announcement Date

Since

Until

  1. Stock Market
  2. Equities
  3. CLDI Stock
  4. News Calidi Biotherapeutics, Inc.